Evaluation of high-dose aflibercept therapy, aqueous humor cytokine changes, and prognostic factors in patients with age-related macular degeneration

Evaluation of high-dose aflibercept therapy, aqueous humor cytokine changes, and prognostic factors in patients with age-related macular degeneration - Evaluation of high-dose aflibercept therapy in patients with age-related macular degeneration

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000058082

Enrollment

120

Registered

2026-01-01

Start date

2025-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neovascular age-related macular degeneration

Interventions

None listed

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: nAMD group: Patients diagnosed with age-related macular degeneration who will receive high-dose aflibercept treatment Control group: Patients undergoing ophthalmic surgery

Exclusion criteria

Exclusion criteria: Cases with comorbid inflammatory diseases such as uveitis Cases that have undergone treatment at another institution with insufficient clinical details Cases in which aqueous humor sampling via anterior chamber paracentesis is judged to be unsafe

Design outcomes

Primary

Measure	Time frame
Change in best-corrected visual acuity from baseline at week 48	—

Countries

Japan

Contacts

Public ContactHikaru Ota

Nagoya University Hospital Ophthalmology

hikaru.betty@gmail.com052-741-2111

Outcome results